Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Key Highlights
- ➤Four aficamten presentations scheduled at HFSA Annual Scientific Meeting 2026
- ➤ACACIA-HCM non-obstructive HCM efficacy results presented October 12, 2026
- ➤ACACIA-HCM exercise-performance analysis presented October 12, 2026
- ➤Cytokinetics (CYTK) plans aficamten nHCM sNDA submission in Q4 2026
Expert Statements
Martin Maron, Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center; National Principal Investigator of SEQUOIA-HCM
“Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results from ACACIA-HCM”
Gregory Lewis, Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing (CPET) Laboratory, Professor of Medicine, Harvard Medical School
“Aficamten Improves Comprehensive Measures of Exercise Performance in Non-Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of ACACIA-HCM”
Yasuhiro Hamatani, Cardiologist, Brigham and Women’s Hospital, Harvard Medical School
“Association Of Aficamten Treatment With Right Ventricular Function And Pulmonary Coupling In Obstructive Hypertrophic Cardiomyopathy: Results From The SEQUOIA-HCM Trial”
Ahmad Masri, Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
“Dosing and Safety of Aficamten for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy in the ACACIA-HCM Trial”
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results from ACACIA-HCM Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center; and National Principal Investigator of SEQUOIA-HCM Date: Monday, October 12, 2026 Session Title: Monday Plenary Session: Late-Breaking Evidence from Novel Therapies to Real-World Outcomes Session Time: 9:00 – 10:30 AM MST Presentation Time: 9:26 – 9:33 AM MST Location: Ballroom BCD, PCC North
Get started
Create a free account to read the full story.